{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:57Z","timestamp":1784020017519,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07988-4","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:23:13Z","timestamp":1780586593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0159-1335","authenticated-orcid":false,"given":"Cynthia L.","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Katsandres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Migliaccio-Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"7988_CR1","unstructured":"Cancer of the Breast (Female) - Cancer stat facts. In: SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed 21 Jan 2025"},{"key":"7988_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","volume":"21","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Costa A, Norton L et al (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242\u2013252","journal-title":"Breast"},{"key":"7988_CR3","unstructured":"CDC (2024) Metastatic female breast cancer incidence. In: United States Cancer Statistics. https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/metastatic-breast-cancer.html. Accessed 21 Jan 2025"},{"key":"7988_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"3","author":"J O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 Suppl 3:20\u201329","journal-title":"Oncologist 10 Suppl"},{"key":"7988_CR5","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.ejca.2014.04.002","volume":"50","author":"A Purushotham","year":"2014","unstructured":"Purushotham A, Shamil E, Cariati M et al (2014) Age at diagnosis and distant metastasis in breast cancer\u2013a surprising inverse relationship. Eur J Cancer 50:1697\u20131705","journal-title":"Eur J Cancer"},{"key":"7988_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E et al (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377:523\u2013533","journal-title":"N Engl J Med"},{"key":"7988_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im S-A, Senkus E et al (2023) OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 184:39\u201347","journal-title":"Eur J Cancer"},{"key":"7988_CR8","unstructured":"Treatment of Stage IV (2025) (Metastatic) Breast cancer. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment\/treatment-of-breast-cancer-by-stage\/treatment-of-stage-iv-advanced-breast-cancer.html. Accessed 21 Jan"},{"key":"7988_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","volume":"22","author":"J O\u2019Shaughnessy","year":"2020","unstructured":"O\u2019Shaughnessy J, Brezden-Masley C, Cazzaniga M et al (2020) Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res 22:114","journal-title":"Breast Cancer Res"},{"key":"7988_CR10","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","volume":"32","author":"C Connors","year":"2025","unstructured":"Connors C, Valente SA, ElSherif A et al (2025) Real-world outcomes with the KEYNOTE-522 regimen in early-stage triple-negative breast cancer. Ann Surg Oncol 32:912\u2013921","journal-title":"Ann Surg Oncol"},{"key":"7988_CR11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981\u20131991","journal-title":"N Engl J Med"},{"key":"7988_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40273-022-01147-5","volume":"40","author":"W Lee","year":"2022","unstructured":"Lee W, Wong WB, Kowal S et al (2022) Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. PharmacoEconomics 40:623\u2013631","journal-title":"PharmacoEconomics"},{"key":"7988_CR13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jval.2021.07.004","volume":"24","author":"W Lee","year":"2021","unstructured":"Lee W, Li M, Wong WB et al (2021) Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. Value Health 24:1746\u20131753","journal-title":"Value Health"},{"key":"7988_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hec.3899","volume":"28","author":"M Li","year":"2019","unstructured":"Li M, Basu A, Bennette CS et al (2019) Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ 28:855\u2013867","journal-title":"Health Econ"},{"key":"7988_CR15","first-page":"S265","volume":"18","author":"Y Sanchez","year":"2012","unstructured":"Sanchez Y, Penrod JR, Qiu XL et al (2012) The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care 18:S265\u2013S271","journal-title":"Am J Manag Care"},{"key":"7988_CR16","first-page":"e340","volume":"23","author":"JT Snider","year":"2017","unstructured":"Snider JT, Batt K, Wu Y et al (2017) The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma. Am J Manag Care 23:e340\u2013e346","journal-title":"Am J Manag Care"},{"key":"7988_CR17","doi-asserted-by":"publisher","unstructured":"Snider JT, Seabury S, Tebeka MG et al (2018) The option value of innovative treatments for metastatic melanoma. Forum Health Econ Policy 21. https:\/\/doi.org\/10.1515\/fhep-2016-0014","DOI":"10.1515\/fhep-2016-0014"},{"key":"7988_CR18","first-page":"1546","volume":"27","author":"WB Wong","year":"2021","unstructured":"Wong WB, To TM, Li M et al (2021) Real-world evidence for option value in metastatic melanoma. J Manag Care Spec Pharm 27:1546\u20131555","journal-title":"J Manag Care Spec Pharm"},{"key":"7988_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.05.014","author":"M Li","year":"2022","unstructured":"Li M, Garrison L Jr, Lee W et al (2022) A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. Value Health. https:\/\/doi.org\/10.1016\/j.jval.2022.05.014","journal-title":"Value Health"},{"key":"7988_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-023-07165-x","volume":"204","author":"J Balma\u00f1a","year":"2024","unstructured":"Balma\u00f1a J, Fasching PA, Couch FJ et al (2024) Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Res Treat 204:237\u2013248","journal-title":"Breast Cancer Res Treat"},{"key":"7988_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J et al (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95:683\u2013690","journal-title":"Br J Cancer"},{"key":"7988_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW (2019) Estimation of clinical trial success rates and related parameters. Biostatistics 20:273\u2013286","journal-title":"Biostatistics"},{"key":"7988_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cpt.194","volume":"98","author":"JA DiMasi","year":"2015","unstructured":"DiMasi JA, Hermann JC, Twyman K et al (2015) A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds. Clin Pharmacol Ther 98:506\u2013513","journal-title":"Clin Pharmacol Ther"},{"key":"7988_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47:20\u201333","journal-title":"J Health Econ"},{"key":"7988_CR25","unstructured":"Microsoft C (2025) Microsoft\u00ae Excel\u00ae for Microsoft 365 MSO"},{"key":"7988_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jval.2024.07.021","volume":"27","author":"M Li","year":"2024","unstructured":"Li M, Elsisi Z, Wong W et al (2024) Does real option value influence oncologists\u2019 treatment recommendations? A survey of US oncologists. Value Health 27:1671\u20131678","journal-title":"Value Health"},{"key":"7988_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2217\/fon-2022-0894","volume":"19","author":"W DeClue","year":"2023","unstructured":"DeClue W, Fisher R, Gooden MD K, et al (2023) Real-world outcomes in metastatic HR+\/HER2-, HER2 + and triple negative breast cancer after start of first-line therapy. Future Oncol 19:909\u2013923","journal-title":"Future Oncol"},{"key":"7988_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387:9\u201320","journal-title":"N Engl J Med"},{"key":"7988_CR29","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T et al (2023) Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol 41:4852\u20134863","journal-title":"J Clin Oncol"},{"key":"7988_CR30","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122","journal-title":"N Engl J Med"},{"key":"7988_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","volume":"9","author":"JM Collins","year":"2021","unstructured":"Collins JM, Nordstrom BL, McLaurin KK et al (2021) A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. Oncol Ther 9:575\u2013589","journal-title":"Oncol Ther"},{"key":"7988_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung NM, Garber JE (2018) BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer 119:141\u2013152","journal-title":"Br J Cancer"},{"key":"7988_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1188\/19.ONF.769-774","volume":"46","author":"M Rosenzweig","year":"2019","unstructured":"Rosenzweig M, West M, Matthews J et al (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46:83\u201391","journal-title":"Oncol Nurs Forum"},{"key":"7988_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djac044","volume":"114","author":"KR Yabroff","year":"2022","unstructured":"Yabroff KR, Han X, Song W et al (2022) Association of medical financial hardship and mortality among cancer survivors in the United States. J Natl Cancer Inst 114:863\u2013870","journal-title":"J Natl Cancer Inst"},{"key":"7988_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12962-023-00503-2","volume":"21","author":"S Rezaei","year":"2023","unstructured":"Rezaei S, Babaei M (2023) A systematic literature review on direct and indirect costs of triple-negative breast cancer. Cost Eff Resour Alloc 21:92","journal-title":"Cost Eff Resour Alloc"},{"key":"7988_CR36","doi-asserted-by":"publisher","unstructured":"Waks G (2022) Genomic profiling advanced breast cancer reveals associations between BRCA mutations resistance CDK4\/6 inhibitors. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/PO.21.00354","DOI":"10.1200\/PO.21.00354"},{"key":"7988_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13058-025-02095-6","volume":"27","author":"LV Ravani","year":"2025","unstructured":"Ravani LV, Bagheri Z, Brufsky AM et al (2025) Comparative efficacy of first- versus second-line CDK4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res 27:146","journal-title":"Breast Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07988-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:00Z","timestamp":1784017800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07988-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7988"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07988-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CLG, SK, KMW, and DLV are employees of Curta Inc which received research support for this study. DE was an employee of Curta Inc at the time analyses were conducted. XX and LP are employees and stockholders of AstraZeneca US. XX and LP are employees and stockholders of AstraZeneca US.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}